1. Home
  2. REPL vs WIW Comparison

REPL vs WIW Comparison

Compare REPL & WIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

N/A

Current Price

$15.65

Market Cap

454.6M

Sector

Health Care

ML Signal

N/A

Logo Western Asset Inflation-Linked Opportunities & Income Fund

WIW

Western Asset Inflation-Linked Opportunities & Income Fund

HOLD

Current Price

$8.34

Market Cap

512.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
REPL
WIW
Founded
2015
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
454.6M
512.1M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
REPL
WIW
Price
$15.65
$8.34
Analyst Decision
Hold
Analyst Count
9
0
Target Price
$5.67
N/A
AVG Volume (30 Days)
5.6M
256.5K
Earning Date
05-21-2026
01-01-0001
Dividend Yield
N/A
11.14%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.50
$8.25
52 Week High
$16.15
$9.03

Technical Indicators

Market Signals
Indicator
REPL
WIW
Relative Strength Index (RSI) 64.26 48.36
Support Level $8.79 $8.34
Resistance Level N/A $8.60
Average True Range (ATR) 1.05 0.04
MACD 0.07 0.00
Stochastic Oscillator 92.27 35.00

Price Performance

Historical Comparison
REPL
WIW

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

About WIW Western Asset Inflation-Linked Opportunities & Income Fund

Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income. Capital appreciation, when consistent with current income, is a secondary investment objective. The fund operates as a single operating segment, which is an investment portfolio.

Share on Social Networks: